Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Xu‐Chao Zhang's publication output changed over time?
ScholarIQpublication output · 2010–2022
Output grew0% over the shown period — from 1 works in 2010 to 1 in 2022.
1
1
1
1
1
4
1
2010201120122016201720192022
What are the most-cited papers on Xu‐Chao Zhang?
ScholarIQmost cited works
Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong‐Yi Dong, Wen‐Zhao Zhong, Xu‐Chao Zhang, Jian Su, Zhi Xie, Si‐Yang Maggie Liu, Hai‐Yan Tu, Hua‐Jun Chen, Yue‐Li Sun, Qing Zhou, Jin‐Ji Yang, Xue‐Ning Yang, Jiaxin Lin, Hong‐Hong Yan, Hao-Ran Zhai, Li‐Xu Yan, Ri-Qiang Liao, Si-Pei Wu, Yi‐Long Wu
Clinical Cancer Research. 2016999 Citations
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia
Qing Lan, Chao A. Hsiung, Keitaro Matsuo, Yun‐Chul Hong, Adeline Seow, Zhaoming Wang, H. Dean Hosgood, Kexin Chen, Jiu-Cun Wang, Nilanjan Chatterjee, Wei Hu, Maria Pik Wong, Wei Zheng, Neil E. Caporaso, Jae Yong Park, Chien‐Jen Chen, Yeul Hong Kim, Young Tae Kim, Maria Teresa Landi, Hongbing Shen, Charles Lawrence, Laurie Burdett, Meredith Yeager, Jeffrey Yuenger, Kevin B. Jacobs, I‐Shou Chang, Tetsuya Mitsudomi, Hee Nam Kim, Gee‐Chen Chang, Bryan A. Bassig, Margaret A. Tucker, Fusheng Wei, Zhihua Yin, Chen Wu, She-Juan An, Biyun Qian, Victor Lee, Daru Lu, Jianjun Liu, Hyo-Sung Jeon, Chin‐Fu Hsiao, Jae Sook Sung, Jin Hee Kim, Yu-Tang Gao, Ying-Huang Tsai, Yoo Jin Jung, Huan Guo, Zhibin Hu, Amy Hutchinson, Wen‐Chang Wang, Robert J. Klein, Charles C. Chung, In‐Jae Oh, Kuan‐Yu Chen, Sonja I. Berndt, Xingzhou He, Wei Wu, Jiang Chang, Xu‐Chao Zhang, Ming-Shyan Huang, Hong Zheng, Junwen Wang, Xueying Zhao, Yuqing Li, Jin Eun Choi, Wu‐Chou Su, Kyong Hwa Park, Sook Whan Sung, Xiao‐Ou Shu, Yuh-Min Chen, Li Liu, Chang Hyun Kang, Lingmin Hu, Chung–Hsing Chen, William Pao, Young‐Chul Kim, Tsung‐Ying Yang, Jun Xu, Peng Guan, Wen Tan, Jian Su, Chih-Liang Wang, Haixin Li, Alan Sihoe, Zhenhong Zhao, Ying Chen, Yi Young Choi, Jen‐Yu Hung, Jun Suk Kim, Ho-Il Yoon, Qiuyin Cai, Chien‐Chung Lin, In Kyu Park, Ping Xu, Jing Dong, Christopher Kim, Qincheng He, Reury-Perng Perng, Takashi Kohno, Sun‐Seog Kweon
S137905309. 2012357 CitationsOPEN ACCESS
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
Xu‐Chao Zhang, Shirley Zhang, Xue‐Ning Yang, Jin‐Ji Yang, Qing Zhou, Lucy Yin, Shejuan An, Jia-Yin Lin, Shiliang Chen, Zhi Xie, Mike Zhu, Xiaolin Zhang, Yi‐Long Wu
S132829192. 2010298 CitationsOPEN ACCESS
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study
Wen‐Zhao Zhong, Ke‐Neng Chen, Chun Chen, Chundong Gu, Jun Wang, Xue‐Ning Yang, Weimin Mao, Qun Wang, Guibin Qiao, Ying Cheng, Lin Xu, Changli Wang, Mingwei Chen, Xiaozheng Kang, Wanpu Yan, Hong‐Hong Yan, Ri-Qiang Liao, Jin‐Ji Yang, Xu‐Chao Zhang, Qing Zhou, Yi‐Long Wu
Journal of Clinical Oncology. 2019268 Citations
Relative Abundance of <i>EGFR</i> Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer
Qing Zhou, Xu‐Chao Zhang, Zhihong Chen, Xiaolu Yin, Jin‐Ji Yang, Chong‐Rui Xu, Hong‐Hong Yan, Hua‐Jun Chen, Jian Su, Wen‐Zhao Zhong, Xue‐Ning Yang, Shejuan An, Bin-Chao Wang, Yi-Sheng Huang, Zhen Wang, Yi‐Long Wu
Journal of Clinical Oncology. 2011247 Citations
Related on ScholarIQ
Guangdong Academy of Medical Sciences
Institution
Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Paper
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia
Paper
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
Paper
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study
Paper
Relative Abundance of <i>EGFR</i> Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer
Paper